DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Dovitinib is an investigational drug.
There have been 51 clinical trials for Dovitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and M.D. Anderson Cancer Center.
Recent Clinical Trials for Dovitinib
|Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma||Seoul National University Hospital||Phase 2|
|Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||Phase 2|
|Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer||National Cancer Institute (NCI)||Phase 1|